PENTHIENATE

First approved in 1954

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H30NO3S
Molecular Weight	340.501
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCC1)C2=CC=CS2

InChI

InChIKey=NEMLPWNINZELKP-UHFFFAOYSA-N

InChI=1S/C18H30NO3S/c1-4-19(3,5-2)12-13-22-17(20)18(21,15-9-6-7-10-15)16-11-8-14-23-16/h8,11,14-15,21H,4-7,9-10,12-13H2,1-3H3/q+1

HIDE SMILES / InChI

Molecular Formula	C18H29NO3S
Molecular Weight	339.493
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.drugfuture.com/chemdata/penthienate-bromide.html | https://www.ncbi.nlm.nih.gov/pubmed/13154614

PENTHIENATE, a synthetic anticholinergic, depresses the motility and secretion of the stomach and reduces the motor activity of the intestine by blocking vagal stimulation. It is used in the treatment of peptic ulcer and dyspepsia.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Spasms 4 Sources: http://www.drugfuture.com/chemdata/penthienate-bromide.html https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA2935-IA243&lpg=PA2935-IA243&dq=PENTHIENATE retrieved from Pharmaceutical Manufacturing Encyclopedia, 3rd Edition: William Andrew Publishing, p. 2935	Primary		Approved 8429	Monodral Approved Use Antispasmodic Launch Date 1954

Doses

Dose	Population	Adverse events
5 mg 3 times / day multiple, oral Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8937366	unhealthy, 63.5 years (range: 36-85 years) n = 20 Health Status: unhealthy Age Group: 63.5 years (range: 36-85 years) Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/8937366	Disc. AE: Swallowing difficult... AEs leading to discontinuation/dose reduction: Swallowing difficult (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/8937366

AEs

AE	Significance	Dose	Population
Swallowing difficult	1 patient Disc. AE	5 mg 3 times / day multiple, oral Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8937366	unhealthy, 63.5 years (range: 36-85 years) n = 20 Health Status: unhealthy Age Group: 63.5 years (range: 36-85 years) Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/8937366

Sourcing

Vendor/Aggregator	ID	URL
AAA Chemistry	AR-1I7286
ABI Chem	AC1L1LQC
ABI Chem	AC1Q65RI
Compound Cloud	6066
Compound Cloud	6067
NCI Plated 2007	61814
NovoSeek	6067
ZINC	ZINC000001690860	http://zinc15.docking.org/substances/ZINC000001690860
ZINC	ZINC000002041344	http://zinc15.docking.org/substances/ZINC000002041344
eMolecules	260195275
eMolecules	76753665

PubMed

Title	Date	PubMed
Mydriatic action of penthienate bromide; a possible substitute for atropine.	1957 Mar 23	13407076
Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline.	1996 Nov 4	8937366

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:00:08 GMT 2023` Edited by `admin` on `Sat Dec 16 02:00:08 GMT 2023`
Record UNII	6LCT38OJV9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENTHIENATE

Common Name

English

PENTHIENATE CATION

Common Name

English

Penthienate [WHO-DD]

Common Name

English

PENTHIENATE ION

Common Name

English

ETHANAMINIUM, 2-((2-CYCLOPENTYL-2-HYDROXY-2-(2-THIENYL)ACETYL)OXY)-N,N-DIETHYL-N-METHYL-

Systematic Name

English

AMMONIUM, DIETHYL(2-HYDROXYETHYL)METHYL-, .ALPHA.-CYCLOPENTYL-2-THIOPHENEGLYCOLATE (ESTER)

Common Name

English

Classification Tree Code System Code

WHO-ATC

A03AB04